Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

The induction of prostatic hypertrophy in the dog with androstanediol.
P C Walsh, J D Wilson
P C Walsh, J D Wilson
Published April 1, 1976
Citation Information: J Clin Invest. 1976;57(4):1093-1097. https://doi.org/10.1172/JCI108353.
View: Text | PDF
Research Article

The induction of prostatic hypertrophy in the dog with androstanediol.

  • Text
  • PDF
Abstract

The effects of androstanediol and estradiol on prostatic growth were investigated in castrate dogs. Estrogens along resulted in no significant change in prostatic weight, whereas androstanediol produced growth comparable to that in uncastrated controls. Androstanediol plus estradiol resulted in an even more striking increase in prostate growth. Approximately half the animals receiving androstanediol alone and all of those receiving androstanediol plus estradiol fulfill the weight and histological criteria for prostatic hypertrophy in the dog. Since both these steroid hormones are presumed to be normal secretory products of the testis, it is possible that they are involved in the pathogenesis of prostatic hypertrophy in the dog.

Authors

P C Walsh, J D Wilson

×

Total citations by year

Year: 2024 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 1985 1984 1983 1982 1981 1980 1979 1978 1977 1974 1970 Total
Citations: 1 1 3 2 2 2 8 4 3 2 2 7 5 5 5 1 3 5 4 10 5 6 8 6 10 5 7 16 10 10 7 15 7 8 11 12 6 10 14 6 12 9 16 14 7 6 1 1 320
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2011 (7)

Title and authors Publication Year
PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia
M Jiang, DW Strand, OE Franco, PE Clark, SW Hayward
Differentiation 2011
Potential prostate cancer drug target: Bioactivation of androstanediol by conversion to dihydrotestosterone
JL Mohler, MA Titus, EM Wilson
Clinical cancer research 2011
Estrogen and androgen signaling in the pathogenesis of BPH
CK Ho, FK Habib
Nature Reviews Urology 2011
Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate Cancer
JL Mohler, MA Titus, S Bai, BJ Kennerley, FB Lih, KB Tomer, EM Wilson
Cancer research 2011
Transarterial Prostatic Embolization: Initial Experience in a Canine Model
F Sun, FM Sánchez, V Crisóstomo, I Díaz-Güemes, C López-Sánchez, J Usón, M Maynar
AJR. American journal of roentgenology 2011
Androgens and estrogens in benign prostatic hyperplasia: past, present and future
TM Nicholson, WA Ricke
Differentiation 2011
Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone: Figure 1
JL Mohler, MA Titus, EM Wilson
Clinical cancer research 2011

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts